TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges

Anita C. Bellail, Ling Qi, Patrick Mulligan, Vaninder Chhabra, Chunhai Hao

Research output: Contribution to journalReview article

140 Scopus citations


Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)34-41
Number of pages8
JournalReviews on Recent Clinical Trials
Issue number1
StatePublished - May 11 2009
Externally publishedYes


  • Apoptosis
  • Cancer
  • Death receptor
  • Monoclonal antibody

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges'. Together they form a unique fingerprint.

Cite this